Patent Application

App. No. 12/921,253

Abstract

Claims (49)

1 . A topical adhesive patch comprising:

a flexible backing having a front side and a back side;

a first formulation positioned on at least a portion on the front side of the backing, in at least a portion on the front side of the backing, or on and in at least a portion on the front side of the backing;

a second formulation positioned on at least a portion on the back side of the backing, in at least a portion on the back side of the backing, or on and in at least a portion on the back side of the backing;

the first formulation comprises an adhesive; and

the second formulation comprising an antibiotic agent, anti-fungal agent, anti-viral agent, or combination thereof.

2 . The adhesive patch of claim 1 wherein the second formulation comprises an anti-viral agent selected from the group of zinc, lysine, foscarnet, 3-deoxythmidin-2-ene, dideoxycytosine, dideoxyinosine, lamivudine, azidothymidine, indinavir, ritonavir, saquinavir, acyclovir, idoxuridine, ribavirin, vidarabine, amantidine, rinantidine, viracea2, cytovene, famciclovir, valaciclovir, penciclovir, nonoxynol-9, pharmaceutically acceptable salts thereof, and combinations thereof.

3 . The adhesive patch of claim 1 wherein the second formulation comprises an anti-viral agent selected from the group of a hypochloride, a hypochloride generating compound, a peroxide, a peroxide generating compound, an organic halide, an organic halide generating compound, and combinations thereof.

4 . The adhesive patch of claim 1 wherein the second formulation comprises an antibiotic agent selected from the group of cilastatin, clavulanic acid, folinic acid, probenecid, pyridoxine, sulbactam, dapsone, ethambutol, isoniazid, pyrazinamide, rifampin, streptomycin, capreomycin, ethionamide, para aminosalicylic acid, cycloserine, ciprofloxacin, nalidixic acid, norfloxacin, ofloxacin, imipenam, meropenem, cilistatin, cefadroxil, cefazolin, cephalexin, cephalothin, cefaclor, cefamandole, cefonicid, cefoxitin, cefuroxine, cefoperazone, cefotaxime, ceftazidime, ceftazidime, ceftizoxime, ceftriaxone, moxalactam, cefepine, bacitracin, vancomycin, aztreonam, amoxicillin, clavulanic acid, benzathine, penicillin g, penicillin v, ampicillin, carbenicillin indamyl, carbenicillin, mezlocillin, piperacillin, ticarcillin, cloxacillin, dicloxacillin, floxacillin, methicillin, nafcillin, oxacillin, colistmethate, polymixin b, trimethoprim, co-trimoxazole, mafenide, sulfadiazine, sodium sulfacetamide, sulfacytine, sulfadiazine, sulfamethoxazole, sulfapyridine, sulfasalazine, sulfisoxazole, chloramphenicol, clindamycin, spectinomycin, azithromycin, clarithromycin, erythrmoycin, erythromycin estolate, spiramycin, chlortetracycline, demeclocycline, doxycycline, minocycline, oxytetracycline, amikacin, kanamycin, neomycin, streptomycin, tobramycin, nitrofurantoin, griseofulvin, potassium iodide, fluconazole, itraconazole, ketoconazole, miconazole, clotrimazole, amphotericin b, nystatin, niclosamide, nifurtimox, piperazine, praziquantel, pyrantel pamoate, ascariasis, thiabendazole, amodiaquine, chloroquine, hydroxychloroquine, mefloquine, primaquine, pyrimethamine, quinidine gluconate, fansidar, diloxanide furoate, melarsoprol, nifurtimox, paromomycin, pentamidine, sodium stibogluconate, suramin, metronidazole, foscarnet, 3-deoxythmidin-2-ene, dideoxycytosine, dideoxyinosine, lamivudine, azidothymidine, indinavir, ritonavir, saquinavir, acyclovir, idoxuridine, ribavirin, vidarabine, amantidine, rinantidine, foscarnet, 3-deoxythmidin-2-ene, dideoxycytosine, dideoxyinosine, lamivudine, azidothymidine, indinavir, ritonavir, saquinavir, acyclovir, idoxuridine, ribavirin, vidarabine, amantidine, rinantidine, triclosan, pharmaceutically acceptable salts thereof, and combinations thereof.

5 . The adhesive patch of claim 1 wherein the second formulation comprises an anti-fungal agent selected from the group of:

[1R-(1R*, 3S*, 5R*, 6R*, 9R*, 11R*, 15S*, 16R*, 17R*, 18S*, 19E, 21E, 23E, 25E, 27E, 29E, 31E, 33R*, 35S*, 36R*, 37S*)]-33-[(3-Amino-3,6-dideoxy-β-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid (Amphotericin B);

5-fluorocytosine (Flucytosine);

2,4-difluoro-α,α 1 -bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol) (Fluconazole);

griseofulvin microsize (Griseofulvin);

(E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethanamine hydrochloride) (Terbinafine);

cis-1-acetyl-4-[4-[(2-(2,4-dichlorophenyl)-2-( 1 H-imadazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxyl]phenyl]piperazine (Ketoconazole);

(∀)-1-[(R*)-sec-butyl]-4-[p-[4-[p-[[(2R*,4S*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylimethyoxy]phenyl]-1-piperazinyl]phenyl]-Δ 2 -1,2,4-triazolin-5-one mixture with (∀)-1-[(R*)-sec-butyl]-4-[p-[4-[p-[[(2S*,4R*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-ylimethoxy]phenyl]-1-piperazinyllphenyl]-Δ 2 -1,2,4-triazolin-5-one or (∀)-1-[(RS)-sec-butyl]-4-[p-[4-[p-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]-methoxy]phenyl]-1-piperazinyllphenyl]-Δ 2 -1,2,4-triazolin-5-one (Itraconazole);

2-chloro-5-hydroxy-1,3-dimethylbenzene (Chloroxylenol);

griseofulvin ultramicrosize (Griseofulvin);

(E)-N-(6,6,-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemanamine hydrochloride (Terbinafine);

6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone (Ciclopirox);

N-4-tert-butyl-benzyl-N-methyl-1-naphthalenemethylamine hydrochloride (Butenafine hydrochloride);

nystatin;

(E)-N-(Cinnamyl-N-methyl-1-naphthalenemethylamine hydrochloride (Naftifine hydrochloride);

1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)-O-[(2,4-dichlorophenyl)methyl]oxime, (Z)-, mononitrate (Oxiconazole nitrate),

6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone (Ciclopirox);

selenium sulfide;

(∀)-1-[4-(p-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]imidazole mononitrate (Butoconazole nitrate);

1-(o-Chloro-α,α-diphenylbenzyl)imidazole (Clotrimazole);

(cis-1-[p-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy phenyl]-4-isopropyl-piperazine (Termayazole);

6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone (ciclopirox);

5-chloro-2-(2,4-dichlorophenoxy)phenol (triclosan);

and combinations thereof.

6 . The adhesive patch of claim 1 wherein the flexible backing of the patch is porous.

7 . The adhesive patch of claim 1 wherein the flexible backing is non-porous.

8 . The adhesive patch of claim 1 wherein the flexible backing of the patch is vapor permeable.

9 . The adhesive patch of claim 1 wherein the flexible backing of the patch comprises a non-woven fabric.

10 . The adhesive patch of claim 1 wherein the flexible backing of the patch comprises polycellulose fibers, polyester fibers, polyurethane fibers, polyolefin fibers, polyamide fibers, cotton fibers, copolyester fibers, films, or any mixture thereof.

11 . The adhesive patch of claim 1 wherein the backing of the patch comprises open cell foam.

12 . The adhesive patch of claim 11 , wherein the open cell foam comprises polyurethane, polyvinyl chloride, polyethylene, or any combination thereof.

13 . The adhesive patch of claim 1 wherein upon contact with skin, the flexible backing of the patch retains the first formulation and the second formulation, and the adhesive patch allows moisture from the skin to pass through the adhesive patch.

14 . The adhesive patch of claim 1 wherein the adhesive is an acrylic ester copolymer, a water-based adhesive, a hot melt adhesive, a pressure sensitive adhesive, a solvent based pressure sensitive adhesive, a polyacrylate, a polyisobutylene, a polybutene, a rubber, a silicone based pressure sensitive adhesive, a polystyrene-polybutadiene-polystyrene block polymer, a polystyrene-polyisoprene-polystyrene block polymer, a polystyrene-poly(ethylene-butylene)-polystyrene block polymer, or any combination thereof.

15 . The adhesive patch of claim 14 wherein the adhesive is an acrylic ester copolymer.

16 . A method of preventing or inhibiting the transmission of a disease selected from a bacterial disease, a fungal disease, a viral disease, and combinations thereof, in a mammal at risk of such disease, the method comprising topically contacting a skin surface of the mammal with a topical adhesive patch of claim 1 , effective to prevent the transmission of the disease;

wherein the disease is selected from a bacterial disease, a fungal disease, a viral disease, and combinations thereof.

17 . The method of claim 16 wherein the bacterial disease comprises bacterial meningitis, conjunctivitis, bacterial pneumonia, pertussis, tonsillitis, infectious diarrhea, cellulitis, impetigo, folliculitis, scalded skin syndrome, urinary tract infections, and combinations thereof.

18 . The method of claim 16 wherein the viral disease comprises the common cold (rhinovirus), human flu (Influenzavirus A, Influenzavirus B, or Influenzavirus C), bronchiolitis, croup, measles, mumps, ruebella, influenza, infectious diarrhea, encephalitis, conjunctivitis, chicken pox, west nile virus, mononucleosis, cold sores, Avian influenza A (H5N1) virus, and combinations thereof.

19 . The method of claim 16 wherein the fungal disease comprises ringworm, athlete's foot, yeast infections, and combinations thereof.

20 . The method of claim 16 wherein the mammal is a human that is younger than 18 years of age.

Assignments (8)